Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.

@article{citeulike:3014000, abstract = {Reports about transfusion-related transmissions of variant Creutzfeldt-Jakob disease have urged the need for more information regarding the risk for prion contaminated units in the blood supply and the safety of transfusion plasma and biopharmaceuticals derived from this precious raw material. According to a possible epidemiological model, the risk in many European countries is the same or lower than that of human immunodeficiency virus. Comprehensive investigations have shown that the prion safety margin of both single-donor and pooled solvent/detergent treated transfusion plasma is high. Furthermore, prophylactic treatment using plasma-derivatives poses a very low risk in terms of prion disease despite extensive lifetime exposure.}, address = {Octapharma Pharmazeutika Produktionsges.m.b.H, Pre-Clinical Research and Development Department, Oberlaaerstrasse 235, A-1100 Vienna, Austria.}, author = {Svae, Tor-Einar E. and Neisser-Svae, Andrea and Bailey, Andrew and Reichl, Herwig and Biesert, Lothar and Schmidt, Torben and Heger, Andrea and R\"{o}misch, J\"{u}rgen }, citeulike-article-id = {3014000}, doi = {10.1016/j.transci.2008.05.006}, issn = {1473-0502}, journal = {Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis}, keywords = {prion\_diseases, risk}, month = {July}, posted-at = {2008-07-17 10:56:38}, priority = {4}, title = {Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.}, url = {http://dx.doi.org/10.1016/j.transci.2008.05.006}, year = {2008} }

TY - JOUR ID - citeulike:3014000 L3 - citeulike-article-id:3014000 TI - Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. JF - Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis AD - Octapharma Pharmazeutika Produktionsges.m.b.H, Pre-Clinical Research and Development Department, Oberlaaerstrasse 235, A-1100 Vienna, Austria. SN - 1473-0502 N2 - Reports about transfusion-related transmissions of variant Creutzfeldt-Jakob disease have urged the need for more information regarding the risk for prion contaminated units in the blood supply and the safety of transfusion plasma and biopharmaceuticals derived from this precious raw material. According to a possible epidemiological model, the risk in many European countries is the same or lower than that of human immunodeficiency virus. Comprehensive investigations have shown that the prion safety margin of both single-donor and pooled solvent/detergent treated transfusion plasma is high. Furthermore, prophylactic treatment using plasma-derivatives poses a very low risk in terms of prion disease despite extensive lifetime exposure. KW - prion_diseases KW - risk AU - Svae, Tor-Einar AU - Neisser-Svae, Andrea AU - Bailey, Andrew AU - Reichl, Herwig AU - Biesert, Lothar AU - Schmidt, Torben AU - Heger, Andrea AU - Römisch, Jürgen PY - 2008/07/09/ UR - http://dx.doi.org/10.1016/j.transci.2008.05.006 ER -